Unite with Fellow Investors
Choose the Best Attorney
Follow Case Progress
id: 516, Created by Stan Vick, Scout
Guardant Health Inc. (GH) Cancer Test Results Disappointment Case
What do I get by joining?
- You will get case updates and receive a payout in case of success
- If you would like to actively participate, you will be connected to the attorney
- No, you do not pay anything out of your pocket neither to us nor to attorney
On December 15, 2022, Guardant Health Inc. (GH) reported that its blood test for colorectal cancer performed worse than expected in a recent study.
On this news, Guardant's shares dropped over 27% and the Company lost more than $1.1 billion of its capitalization, seriously damaging investors.
Guardant Health went public in 2018 at $19 a share. It hit its all-time high at $179 in February 2021. And now it trades at $30 for a common stock.
- In a press release, the Company said its test accurately found the presence of cancer 83% of the time. But the screening also delivered false positive results 10% of the time, and it was only to detect the presence of benign tumors that can turn cancerous 13% of the time.
- Investors were expecting better results, Citigroup Inc. analyst Patrick Donnelly told Bloomberg. In particular, they were looking for Guardant's test to detect cancer at least 85% of the time and to more frequently identify possibly pre-cancerous tumors, he told Bloomberg.
- The results indicate Guardant's test won't be an adequate substitute for colonoscopies or Cologuard, a screening that looks for signs of cancer in patients' stool, Jeffries analyst Brandon Couillard told Bloomberg.
Investors have reasons to suspect that the Company and Management did not properly inform shareholders about the prospect of its candidate and now it led to the dramatic depreciation of their shareholdings.
Failure to Disclose,
Breach of Fiduciary duty,
Shock Event Date
15 December 2022